Endovascular Management of Intracranial Dural Arteriovenous Fistulas: Transarterial Approach


AJNR Am J Neuroradiol published online 7 October 2021
http://www.ajnr.org/content/early/2021/10/07/ajnr.A7296

This information is current as of December 7, 2023.
Endovascular Management of Intracranial Dural Arteriovenous Fistulas: Transarterial Approach


ABSTRACT

SUMMARY: In this second of 3 review articles on the endovascular management of intracranial dural AVFs, we discuss transarterial treatment approaches. The treatment goal is to occlude the fistulous point, including the most distal portion of the arterial supply together with the most proximal portion of the draining vein (ie, the “foot” of the vein), which can be accomplished with liquid embolic agents via transarterial access. Anatomic factors to consider when assessing the safety and efficacy of a transarterial approach using liquid embolic agents include location, angioarchitecture, and proximity of arterial feeders to both the vasa nervorum of adjacent cranial nerves and the external carotid–internal carotid/vertebral artery anastomoses. Anatomic locations typically favorable for transarterial approaches include but are not limited to the transverse/sigmoid sinus, cerebral convexity, and superior sagittal sinus. In this review article, we discuss the technical approaches, outcomes, potential complications, and complication avoidance strategies for transarterial embolization.

ABBREVIATIONS: dAVF = dural AVF; EC-IC = external carotid to internal carotid; EVOH = ethylene-vinyl alcohol copolymer; TAE = transarterial embolization; TVE = transvenous embolization

In this second of 3 review articles on the endovascular management of intracranial dural AVFs (dAVFs), we discuss transarterial treatment approaches. Transarterial embolization (TAE) using glue or particles was the initial endovascular approach for intracranial dAVFs since the beginning of interventional neuroradiology in the 1970s. Glue embolization could achieve angiographic cure if the fistulous point was reached. However, this was frequently not achievable due to limitations in obtaining distal penetration using glue, which polymerizes rapidly on contact with blood. In addition, cure via occlusion of the fistulous point using glue is more easily achieved when there is direct cortical venous drainage (Borden type III, Cognard type III–IV dAVFs) but is difficult when venous drainage is into the sinus (Borden I–II, Cognard I–II). Adhesion of the microcatheter resulting in removal difficulty is also a concerning limitation associated with glue. Similarly, particle embolization is limited by the inherent difficulty in controlling its distribution during injection as well as the temporary nature of the achieved occlusion with high rates of recanalization.

The creation of ethylene-vinyl alcohol copolymer (EVOH) as a liquid embolic agent in 2005 allowed more controlled distal penetration of the liquid embolic, resulting in improved fistula occlusion rates, while reducing the risk of cranial nerve palsy or parenchymal arterial infarction. EVOH solidifies at a markedly slower rate than glue, forming a lava-like morphology that hardens during 20–30 minutes. This allows pauses during embolization, plug formation to allow later distal penetration, controlled reflux into adjacent feeders, and a greater ability to target embolization material toward the fistulous point. The distal penetration and diffusion of EVOH allows occlusion of multiple feeders from a single microcatheter position. Disadvantages include local inflammation, which can cause transient or, rarely, permanent cranial neuropathy when treating cavernous or hypoglossal canal dAVFs and increased porosity relative to glue, allowing dAVF recurrence.

In addition, the creation of venous sinus occlusion balloons allowed greater rates of sinus preservation and angiographic cure when treating Borden/Cognard I–II dAVFs via an arterial approach. In this article, we discuss the treatment goals,
favorable anatomic locations, technical approaches, outcomes, potential complications, and complication avoidance strategies for TAE using modern liquid embolic agents (EVOH).

**Treatment Goal**

TAE approaches to intracranial dAVFs aim to occlude the fistulous point and the foot of the draining vein via a distal artery position. Occlusion of arterial feeders without penetration of liquid embolic into the proximal portion of the draining vein is unlikely to achieve a permanent cure owing to the vast potential anastomotic network of dural branches that may provide supply to the shunt. Rather, proximal ligation of arterial feeders often induces new arterial feeders to the fistula that are more difficult to access from an endovascular approach, while blocking the initially accessible pathways. Similarly, proximal occlusion of an arterial feeder will not address the overall management goal when treating dAVFs, which is to prevent future hemorrhage or neurologic deficits arising from cortical venous reflux. While proximal occlusion can be used as a method of reducing intraoperative blood loss when planning microsurgical disconnection as the curative treatment, it is of little value when aiming for an endovascular cure.

Therefore, before embarking on TAE, the interventionist must judge the likelihood of achieving a suitable distal position with the microcatheter to allow an angiographic cure. Such a position must allow preservation of the vasa nervorum adjacent to cranial nerves and avoidance of external carotid to internal carotid (EC-IC) artery anastomoses (ie, the existence of a reasonable safety margin for EVOH arterial reflux). In the absence of these favorable factors, alternative treatment approaches such as transvenous embolization (TVE) or microsurgical disconnection should be considered.

**Anatomic Locations**

Anatomic locations of dAVFs that are typically suitable for TAE include the cerebral convexity, transverse sinus (combined with balloon sinus protection if the sinus is still used; Fig 1), lateral tentorial region, and superior sagittal sinus (with balloon sinus protection if the fistula is within the main venous compartment of the sinus). These locations are usually suitable for TAE due to the existence of a relative safe distance between the fistulous point and the cranial nerves or major EC-IC anastomoses, which lie predominantly over the ventral skull base. In addition, the dural arteries supplying AVFs in these locations (often partly supplied by relatively straight branches of the middle meningeal artery) allow easier technical access for a microcatheter.

Locations that may be suitable for TAE, either alone or in combination with TVE or microsurgical disconnection depending on angioarchitecture, include the petrous ridge (taking care to avoid seventh nerve palsy) (Figs 2 and 3) and medial tentorial, ethmoidal, and falcirotentorial junction dAVFs. Thus, most dorsal and lateral epidural locations can be considered for TAE.

Locations not typically suitable for TAE are the cavernous sinus and ventral aspect of the foramen magnum, corresponding to ventral epidural locations where cranial nerves traverse the skull base. TAE approaches to these locations pose a significant risk of cranial nerve palsy (III–VI for cavernous sinus, IX–XII for the foramen magnum or penetration across EC-IC anastomoses, resulting in parenchymal infarction. TAE approaches to these ventral epidural locations adjacent to the sphenoid bone and basiocciput should be avoided, and a TVE approach should be considered in the first instance.

**Technical Approaches**

When using EVOH for TAE treatments, there are 4 main technical approaches that can be used (and may be combined in some instances):

1. Plug formation
2. Pressure cooker (dual microcatheter)
3. Dual-lumen balloon
4. Balloon sinus protection.

The choice of technique is dependent on knowledge of the anatomic safety margins to the nearby vasa nervorum or EC-IC anastomoses, as well as the nature of the venous drainage (eg, balloon sinus protection for type I and II dAVFs). On the basis of this knowledge, the interventionist should set anatomic safety margins on the angiography monitor, beyond which they will not allow EVOH to travel.

When embolizing with EVOH, transmission of embolic material toward these margins should be managed by pausing embolization for 30 seconds to 2 minutes to allow solidification of the agent before recommencing. If reflux persists on recommencement, the pause period should be increased appropriately. This process of intermittent pausing will be repeated several times until the liquid embolic travels toward the desired target of the fistulous point.

**Technical Approaches: Plug Formation**

Plug formation was the original technique used with the widespread release of EVOH for intracranial embolization and is still the most common technique. It relies on slow administration of EVOH via the microcatheter tip, often in slow, intermittent bursts for 5–10 minutes, until a plug of semi-solidified EVOH has formed around the tip, preventing further reflux of the agent. The process of intermittent pausing will be required to achieve a stable and reliable plug, as described above.

The technique is dependent on a degree of controlled reflux within anatomic constraints to form the plug. Once the plug is formed, further administration of EVOH will travel antegrade toward the fistulous point, allowing potential angiographic cure of the lesion. If a detachable-tip microcatheter is not used or the degree of reflux extends proximal to the detachable tip, the interventionist has approximately 20–30 minutes from the time of the first EVOH administration to complete the embolization (the time for the EVOH to completely solidify) to be readily able to remove the microcatheter. If the microcatheter cannot be removed due to adherence with the plug (ie, glued in), the microcatheter may be cut at the skin exit site and will incorporate into the vessel wall with time (though posing a risk of thromboembolic events) or can be removed with the aid of a snare using a modified monorail technique.

The most significant predictor of the length of reflux required to form a stable plug is the diameter of the vessel. When the
microcatheter tip is occlusive in the lumen (ie, a small diameter),
the plug will form rapidly and the flow becomes antegrade soon af-
Figure 3 demonstrates successful use of the plug-formation
Figure 3 demonstrates successful use of the plug-formation

If the lumen diameter is several times greater than the micro-
catheter (ie, a large diameter), a long segment of reflux will be
required to create a reliable plug. In our opinion, when a large
lumen diameter is present, use of a pressure cooker technique is
advisable to avoid the excess time and reflux necessary to create a
reliable plug. When there is a short anatomic safety margin, a
pressure cooker or a dual-lumen balloon technique is also neces-
sary to avoid reflux-related complications.15

Cerebral convexity dAVFs are often suitable candidates for
plug formation as an embolization technique.19 We would hesi-
tate to use branches of the occipital artery in the first instance as
an embolization point for the plug formation technique, owing to
their tortuous nature, invariable presence of transosseous small
channels feeding the dAVF from the occipital artery that are diffi-
cult to cross, the presence of occipital-to-vertebral artery anasto-
omes, and the potential for reflux to the stylomastoid branch of
the occipital/posterior auricular arteries, a branch that supplies
the facial nerve.15

**Technical Approaches: Pressure Cooker (Dual-
Microcatheter) Technique**

The pressure cooker technique was first described by Chapot
et al.21 in 2014, for the treatment of brain arteriovenous malforma-
tions following the release of detachable-tip microcatheters. It has
since been adapted for the treatment of dAVFs.22 This technique
uses 2 microcatheters side-by-side and thus requires a guide or in-
termediate catheter large enough to accommodate both (usually a
6F system). One microcatheter has a detachable tip (commercially
available in 15–50 mm lengths), while the second is usually a
standard coiling microcatheter. In tortuous anatomy, standard coiling catheters can be difficult to navigate distally, and the use of lower profile coils via smaller microcatheters is an alternative option.

Once the detachable-tip microcatheter has been positioned distally in the arterial feeder, the second microcatheter is advanced side-by-side so that it ends adjacent to the detachable segment of the first microcatheter. A plug of coils followed by glue for complete occlusion is formed with the second microcatheter so that the arterial feeder is occluded adjacent to the detachable segment and reflux will be minimized during embolization, resulting in forced antegrade flow (hence the name “pressure cooker”). A modified version of the technique using only glue and EVOH without the need for coils has also been described. The second microcatheter is then removed, and embolization of the dAVF is commenced using EVOH via the detachable-tip microcatheter.

At the end of the procedure, the detachable tip is detached and the remainder of the microcatheter is removed, taking care not to dislodge the coil/glue plug that lies adjacent to it. An example of a modified pressure cooker technique (with balloon sinus protection) to embolize a transverse sinus Cognard type IIa+b dAVF is demonstrated in Fig 1.

The major advantage of the pressure cooker technique is the ability to minimize reflux and allow antegrade flow of EVOH into the fistulous point. Thus, it is a useful technique when the anatomic safety margin is short or the lumen of the vessel is large (relative to the microcatheter). In addition, there is no time limit during embolization for more extensive malformations because reflux is minimized and there is little risk of “gluing in” the microcatheter. The major disadvantage is the additional time required to place a second microcatheter and form the coil/glue plug; in our experience, this additional time is largely offset by the time saved during embolization using this technique.

**Technical Approaches: Dual-Lumen Balloon**

Dual-lumen balloon microcatheters have 1 lumen for inflation of the balloon and a separate lumen for placement of a guidewire or administration of the embolic agent. With the balloon inflated, occlusion of the arterial feeder can be achieved allowing antegrade flow of EVOH toward the fistulous point via the second lumen while limiting reflux. Thus, this can also be considered a modification of the pressure cooker technique.

The advantages of a dual-lumen balloon are the same as those of a traditional pressure cooker technique, ie, maintained antegrade flow and limited reflux. In addition, the use of a single microcatheter in this technique can be undertaken through a smaller guiding system. Embolization and fluoroscopy times are markedly reduced. However, in our experience, the seal created by the balloon can be suboptimal. In addition, these dual-lumen balloon microcatheters do not track as easily in tortuous vessels. The recent release of low-profile dual-lumen balloons may help to overcome this limitation.

**Technical Approaches: Balloon Sinus Protection**

In Borden/Cognard type I and II dAVFs, the venous drainage is directly into a dural venous sinus or an adjacent parasinus (common arterial collector) in the wall of the sinus. TAE of such dAVFs necessarily predisposes to embolic agent transmission into the dural venous sinus, leading to occlusion. There is also a risk of reflux back to the pulmonary circulation.

In high-flow fistulas, occlusion of the fistulous point, which can be multiple, is difficult to achieve without occluding the sinus first (eg, with coils). If the dural sinus is needed to drain the brain, it
is necessary to preserve this channel using dural venous sinus-protection balloons while treating the dAVF using TAE. Such preservation maintains the sinus lumen for future procedures if required as well as avoiding potential intracranial venous complications. This technique can be considered a reconstructive treatment approach, compared with the traditional deconstructive approach using transvenous coil occlusion.

These sinus occlusion balloons (typically 8–10 mm in diameter) are placed via transvenous access into the relevant sinus and inflated so that they occlude the sinus. TAE with EVOH via one of the arterial feeders then allows occlusion of the fistulous point as well as controlled reflux into adjacent arterial feeders of relevance, resulting in an angiographic cure while preserving the particles and/or coils used in 27% of cases; the choice of embolic agent evolved with time, resulting in a heterogeneous treatment sample. The lack of regulatory approval for EVOH use in Japan for the treatment of intracranial dAVFs is from the Japanese Registry of Neuroendovascular Therapy, which reported clinical and angiographic outcomes from 858 TAE procedures. In this large cohort of patients, total occlusion was achieved in 26% of procedures, and subtotal occlusion, in a further 29% (combined 55%). However, this study incorporated a wide variety of embolic agents, including glue in 61% of cases and EVOH in only 13% of cases, with
angiographic cure rate for type I and II dAVFs. EVOH using a dual-lumen balloon with additional balloon venous sinus balloon protection from 50% to 67%.37

Moenninghoff et al,38 in 2020, described outcomes from TAE using EVOH in 75 patients, reporting a complete occlusion rate of 77%, with 60% of cases cured after a single session. Our own results at Toronto Western Hospital in the EVOH era are similar (65.1% angiographic cure rate with TAE). Overall, these results indicate that TAE angiographic cure rates have increased significantly in the EVOH era to approximately two-thirds of cases.

Outcomes specific to each of the 4 TAE treatment approaches detailed above are described in smaller samples only, and the choice of approach is usually tailored to patient-specific angioarchitecture as well as the preferences of the interventionalist. The use of TAE with EVOH in combination with balloon sinus occlusion for type I and II dAVFs is increasingly reported, most often for the treatment of transverse/sigmoid sinus dAVFs. Vollherbst et al,11 in 2018, reported complete angiographic occlusion of the dAVF in 86.4% when using balloon sinus occlusion in a series of 22 patients. Pichowiak et al,39 in 2017, reported angiographic occlusion in 8 of 9 patients with transverse/sigmoid sinus dAVFs treated via TAE with EVOH using a dual-lumen balloon with additional balloon venous sinus protection. These results, though limited by small sample sizes, suggest that the use of venous sinus balloon protection in combination with TAE using EVOH has a high angiographic cure rate for type I and II dAVFs.

Complications

The Japanese Registry of Neuroendovascular Therapy results from 858 TAE procedures describes an overall complication rate of 6.9%, with 30-day morbidity of 2.5% and mortality of 1.0%. The most common complications of TAE were arterial ischemic events (2.3%; with 1.3% distal thromboembolism, 1.0% arterial occlusion), vessel perforation (0.9%), venous occlusion with non-hemorrhagic deficits (0.6%), venous occlusion with hemorrhage (0.5%), vessel rupture (0.3%), and a nonretrievable microcatheter (ie, glued in [0.2%]).15 In this large cohort, complications related to TAE were more common during treatment of dAVFs involving the transverse/sigmoid sinus (8%), tentorial (including Petrous ridge, 12.4%), craniovertebral junction (17.7%), and anterior cranial fossa (17.4%).36

These complication rates are consistent with our own experience at Toronto Western Hospital, in which 3 of 106 patients treated by TAE as the primary approach had an arterial infarct (2.8%) and 2 patients had periprocedural symptomatic intracranial hemorrhage (1.9%; subarachnoid, n = 1; intracerebral n = 1). No patients had cranial nerve palsy. Retrospective review of contributing factors in all 3 of our TAE cases complicated by arterial infarction identified penetration of embolic agents across EC-IC anastomoses into the cerebral parenchymal circulation as the underlying cause.

Avoiding Cranial Neuropathy during TAE: Anatomic Considerations

The absence of cranial neuropathy as a complication of TAE in our cohort at Toronto Western Hospital represents a concerted effort to preserve the vasa nervosum during TAE procedures. Detailed angiographic assessment of the dAVF is essential to identify the proximity of the vasa nervosum to the dAVF and its feeders. A detailed discussion of the arterial supply to the cranial nerves is beyond the scope of this article but is well-described in the literature.14,18,40

As a general principle, anatomic location of the dAVF in proximity to the sphenoid bone, basicoccygial, or petrous temporal bone should alert the neuroradiologist to the potential risk of cranial neuropathy from TAE. This risk is because the major transit points of the cranial nerves through the skull base are across these osseous structures, and their vasa nervosum lie in proximity to these foramina.14 The ventral anatomic locations that are relative contraindications for TAE include cavernous, ventral foramen magnum, and, to a lesser extent, ethmoid and petrous dAVFs.

Cavernous dAVFs (indirect types, Barrow types B–D)41 are frequently supplied by branches of the inferolateral trunk, meningohypophyseal trunk, cavernous and ophthalmic branches of the middle meningeal artery, vidian artery, and artery of the foramen rotundum, all of which can potentially provide arterial supply to cranial nerves III–VI.14,18 In addition, the cavernous and orbital regions represent major sites of EC-IC anastomoses.14 Similarly, ventral foramen magnum/condylar dAVFs are typically supplied by the jugular and hypoglossal branches of the neuromeningeal division of the ascending pharyngeal artery, also supplying nerves IX–XII.14,40 Thus, transarterial approaches to these locations should be strongly reconsidered, while transvenous approaches are well-established.36,42,43

Petrous dAVFs always receive at least partial supply from the facial nerve arterial arcade, an anatomic arterial arc supplying the facial nerve and formed by the petrous branch of the middle meningeal artery and the stylomastoid branch of the posterior auricular/occipital artery (Figs 2A and 3A).15,44 In our experience, TAE can be attempted for petrous dAVFs when there is, at minimum, a 20-mm margin from the planned embolization point back to the facial nerve arterial arcade, to allow a detachable-tip microcatheter (minimum tip length, 15 mm) to be used while preserving the arcade (Fig 3).13 Ethmoid dAVFs pose a greater risk to the central retinal artery during TAE rather than actual cranial neuropathy; microsurgical disconnection is usually preferred, though transvenous approaches are increasingly popular.45

Avoiding Embolization of EC-IC Anastomoses: Anatomic Considerations

Major EC-IC anastomotic pathways are predominantly distributed within 3 regions of the skull base and have been extensively described by Geibprasert et al, 2009.14

1. Orbital: Anastomoses between branches of the middle meningeal artery/internal maxillary artery and the ophthalmic artery
2. Petrocavernous: Anastomoses between branches of the middle meningeal artery/internal maxillary artery and the branches of the cavernous segment of the ICA (inferolateral trunk, meningohypophyseal trunk)
CONCLUSIONS

TAE is a useful and effective treatment option for dorsal and lateral intracranial dAVFs. Anatomic knowledge of the vasa nervosum and EC-IC anastomoses is essential in avoiding complications during TAE procedures.


REFERENCES


The application of Copernic RC Balloon and a detailed analysis of occlusion, recurrence, and clinical outcomes in an endovascular library of 260 dural arteriovenous fistulas. J Neurosurg 2017;126:1884–93 CrossRef Medline


